Anti-Venom Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

Published Mar 18, 2023

Length 145 Pages

SKU # IMRC17854637

Description

Anti-Venom Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

Market Overview:

The global anti-venom market size reached US$ 1,096.1 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 1,644.9 Million by 2028, exhibiting a growth rate (CAGR) of 6.7% during 2023-2028.

Anti-venoms are purified antibodies used to stop snake venom from binding to tissues and causing severe allergic reactions, blood-clotting, muscle injury, or nervous system problems. They can prevent or reverse the snakebite envenoming effects, which help minimize mortality and morbidity. They are obtained from different animal species, such as snakes, funnel web spiders, stonefish, redback spiders, and box jellyfish, using different technologies. Presently, the type of anti-venom generally used depends on the history and examination of the patient and geographic, clinical, and pathologic factors.

Anti-Venom Market Trends:

The risk of snakebite envenoming is a public health hazard that people, especially in the rural areas, experience on a regular basis. It causes occupational injury among several agricultural workers and hunters, which represents one of the key factors driving the need for safe, effective, and affordable anti-venoms. In addition, open-plan housing and the practice of sleeping on the floor, common in tropical regions, can expose people to bites from nocturnal and highly venomous snakes and cause serious health problems. These health problems usually include kidney failure, severe paralysis that prevents breathing, bleeding disorders that can lead to fatal hemorrhage, and severe local tissue destruction that can cause permanent disability and result in limb amputation. This, in turn, is catalyzing the demand for anti-venoms across the globe. Apart from this, there is an introduction of snake venom detection kits with a rapid enzyme immunoassay for in vitro detection and immunological identification of snake venom in samples from bite sites, urine, plasma, blood, or other tissues and body fluids. This is anticipated to offer lucrative growth opportunities to industry players and drive the overall market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global anti-venom market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on species, anti-venom type, mode of action and end user.

Breakup by Species:

Snake
Scorpion
Spider
Others

Breakup by Anti-venom Type:

Polyvalent Anti-venom
Monovalent Anti-venom

Breakup by Mode of Action:

Cytotoxic
Neurotoxic
Haemotoxic
Cardiotoxic
Myotoxic
Others

Breakup by End User:

Hospitals
Clinics
Ambulatory Surgical Centers

Breakup by Region:

North America

United States
Canada

Asia-Pacific

China
Japan
India
South Korea
Australia
Indonesia
Others

Europe

Germany
France
United Kingdom
Italy
Spain
Russia
Others

Latin America

Brazil
Mexico
Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Bharat Serums and Vaccines Limited (BSV), Boehringer Ingelheim International GmbH, Boston Scientific Corporation, CSL Limited, Haffkine Bio-Pharmaceutical Corporation Limited, Incepta Pharmaceuticals Limited, Merck & Co. Inc., Merck KGaA, MicroPharm Limited, Pfizer Inc. and Rare Disease Therapeutics Inc.

Key Questions Answered in This Report:

What was the size of the global anti-venom market in 2022?
What is the expected growth rate of the global anti-venom market during 2023-2028?
What has been the impact of COVID-19 on the global anti-venom market?
What are the key factors driving the global anti-venom market?
What is the breakup of the global anti-venom market based on the species?
What is the breakup of the global anti-venom market based on the anti-venom type?
What is the breakup of the global anti-venom market based on the mode of action?
What is the breakup of the global anti-venom market based on the end user?
What are the key regions in the global anti-venom market?
Who are the key players/companies in the global anti-venom market?

1 Preface
2 Scope and Methodology: 2.1 Objectives of the Study; 2.2 Stakeholders; 2.3 Data Sources; 2.3.1 Primary Sources; 2.3.2 Secondary Sources; 2.4 Market Estimation; 2.4.1 Bottom-Up Approach; 2.4.2 Top-Down Approach; 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction: 4.1 Overview; 4.2 Key Industry Trends
5 Global Anti-venom Market: 5.1 Market Overview; 5.2 Market Performance; 5.3 Impact of COVID-19; 5.4 Market Forecast
6 Market Breakup by Species: 6.1 Snake; 6.1.1 Market Trends; 6.1.2 Market Forecast; 6.2 Scorpion; 6.2.1 Market Trends; 6.2.2 Market Forecast; 6.3 Spider; 6.3.1 Market Trends; 6.3.2 Market Forecast; 6.4 Others; 6.4.1 Market Trends; 6.4.2 Market Forecast
7 Market Breakup by Anti-venom Type: 7.1 Polyvalent Anti-venom; 7.1.1 Market Trends; 7.1.2 Market Forecast; 7.2 Monovalent Anti-venom; 7.2.1 Market Trends; 7.2.2 Market Forecast
8 Market Breakup by Mode of Action: 8.1 Cytotoxic; 8.1.1 Market Trends; 8.1.2 Market Forecast; 8.2 Neurotoxic; 8.2.1 Market Trends; 8.2.2 Market Forecast; 8.3 Haemotoxic; 8.3.1 Market Trends; 8.3.2 Market Forecast; 8.4 Cardiotoxic; 8.4.1 Market Trends; 8.4.2 Market Forecast; 8.5 Myotoxic; 8.5.1 Market Trends; 8.5.2 Market Forecast; 8.6 Others; 8.6.1 Market Trends; 8.6.2 Market Forecast
9 Market Breakup by End User: 9.1 Hospitals; 9.1.1 Market Trends; 9.1.2 Market Forecast; 9.2 Clinics; 9.2.1 Market Trends; 9.2.2 Market Forecast; 9.3 Ambulatory Surgical Centers; 9.3.1 Market Trends; 9.3.2 Market Forecast
10 Market Breakup by Region: 10.1 North America; 10.1.1 United States; 10.1.1.1 Market Trends; 10.1.1.2 Market Forecast; 10.1.2 Canada; 10.1.2.1 Market Trends; 10.1.2.2 Market Forecast; 10.2 Asia-Pacific; 10.2.1 China; 10.2.1.1 Market Trends; 10.2.1.2 Market Forecast; 10.2.2 Japan; 10.2.2.1 Market Trends; 10.2.2.2 Market Forecast; 10.2.3 India; 10.2.3.1 Market Trends; 10.2.3.2 Market Forecast; 10.2.4 South Korea; 10.2.4.1 Market Trends; 10.2.4.2 Market Forecast; 10.2.5 Australia; 10.2.5.1 Market Trends; 10.2.5.2 Market Forecast; 10.2.6 Indonesia; 10.2.6.1 Market Trends; 10.2.6.2 Market Forecast; 10.2.7 Others; 10.2.7.1 Market Trends; 10.2.7.2 Market Forecast; 10.3 Europe; 10.3.1 Germany; 10.3.1.1 Market Trends; 10.3.1.2 Market Forecast; 10.3.2 France; 10.3.2.1 Market Trends; 10.3.2.2 Market Forecast; 10.3.3 United Kingdom; 10.3.3.1 Market Trends; 10.3.3.2 Market Forecast; 10.3.4 Italy; 10.3.4.1 Market Trends; 10.3.4.2 Market Forecast; 10.3.5 Spain; 10.3.5.1 Market Trends; 10.3.5.2 Market Forecast; 10.3.6 Russia; 10.3.6.1 Market Trends; 10.3.6.2 Market Forecast; 10.3.7 Others; 10.3.7.1 Market Trends; 10.3.7.2 Market Forecast; 10.4 Latin America; 10.4.1 Brazil; 10.4.1.1 Market Trends; 10.4.1.2 Market Forecast; 10.4.2 Mexico; 10.4.2.1 Market Trends; 10.4.2.2 Market Forecast; 10.4.3 Others; 10.4.3.1 Market Trends; 10.4.3.2 Market Forecast; 10.5 Middle East and Africa; 10.5.1 Market Trends; 10.5.2 Market Breakup by Country; 10.5.3 Market Forecast
11 SWOT Analysis: 11.1 Overview; 11.2 Strengths; 11.3 Weaknesses; 11.4 Opportunities; 11.5 Threats
12 Value Chain Analysis
13 Porters Five Forces Analysis: 13.1 Overview; 13.2 Bargaining Power of Buyers; 13.3 Bargaining Power of Suppliers; 13.4 Degree of Competition; 13.5 Threat of New Entrants; 13.6 Threat of Substitutes
14 Price Analysis
15 Competitive Landscape: 15.1 Market Structure; 15.2 Key Players; 15.3 Profiles of Key Players; 15.3.1 Bharat Serums and Vaccines Limited (BSV); 15.3.1.1 Company Overview; 15.3.1.2 Product Portfolio; 15.3.2 Boehringer Ingelheim International GmbH; 15.3.2.1 Company Overview; 15.3.2.2 Product Portfolio; 15.3.3 Boston Scientific Corporation; 15.3.3.1 Company Overview; 15.3.3.2 Product Portfolio; 15.3.3.3 Financials; 15.3.3.4 SWOT Analysis; 15.3.4 CSL Limited; 15.3.4.1 Company Overview; 15.3.4.2 Product Portfolio; 15.3.4.3 Financials; 15.3.4.4 SWOT Analysis; 15.3.5 Haffkine Bio-Pharmaceutical Corporation Limited; 15.3.5.1 Company Overview; 15.3.5.2 Product Portfolio; 15.3.6 Incepta Pharmaceuticals Limited; 15.3.6.1 Company Overview; 15.3.6.2 Product Portfolio; 15.3.7 Merck & Co. Inc.; 15.3.7.1 Company Overview; 15.3.7.2 Product Portfolio; 15.3.7.3 Financials; 15.3.7.4 SWOT Analysis; 15.3.8 Merck KGaA; 15.3.8.1 Company Overview; 15.3.8.2 Product Portfolio; 15.3.8.3 Financials; 15.3.8.4 SWOT Analysis; 15.3.9 MicroPharm Limited; 15.3.9.1 Company Overview; 15.3.9.2 Product Portfolio; 15.3.10 Pfizer Inc.; 15.3.10.1 Company Overview; 15.3.10.2 Product Portfolio; 15.3.10.3 Financials; 15.3.10.4 SWOT Analysis; 15.3.11 Rare Disease Therapeutics Inc.; 15.3.11.1 Company Overview; 15.3.11.2 Product Portfolio

Pricing

Currency Rates

Single User Email from Publisher $2,999
Five User License Fulfilled by Publisher $3,999
Global Site License Email from Publisher $4,999

How Do Licenses Work?

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.

Chat Now